MYK 491

Drug Profile

MYK 491

Alternative Names: MYK-491; SAR 440181

Latest Information Update: 03 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator MyoKardia
  • Developer MyoKardia; Sanofi
  • Class Cardiovascular therapies; Small molecules
  • Mechanism of Action Cardiac myosin stimulants; Genetic process modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Dilated cardiomyopathy

Most Recent Events

  • 07 Aug 2017 MyoKardia plans a phase I trial for Dilated cardiomyopathy in unknown countries by the end of 2017
  • 16 Jan 2017 Phase-I clinical trials in Dilated cardiomyopathy (In volunteers) in Australia (PO) (NCT03062956)
  • 31 Dec 2016 MyoKardia and Sanofi extend research collaboration for MYK 491
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top